{
    "clinical_study": {
        "@rank": "40128", 
        "acronym": "ALTN", 
        "arm_group": {
            "arm_group_label": "anlotinib hydrochloric capsule", 
            "arm_group_type": "Experimental", 
            "description": "dosage form:capsule dosage:5mg,10mg,16mg,12mg frequency:once one day duration:Continuous two weeks then stop a week"
        }, 
        "brief_summary": {
            "textblock": "Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug\n      Administration\uff08SFDA\uff09 which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co.,\n      Ltd.\n\n      ALTN is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2\n      and VEGFR3. It has the obvious resistance to new angiogenesis."
        }, 
        "brief_title": "A Phase I Study of Anlotinib Hydrochloric Capsule on Tolerance and Pharmacokinetics", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Cancer", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The primary objective of this trial is to explore the maximum tolerated dose(MTD),\n      dose-limiting toxicity(DLT) of ALTN and rational dosage regimen for phase II study, to\n      investigate the pharmacokinetics with single and multiple doses of ALTN from\n      5mg/d,10mg/d,16mg/d,12mg."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. late malignant tumor patients diagnosed with the pathological and/or cytological;\n\n          2. lack of the standard treatment or treatment failure;\n\n          3. 18-65years, ECOG:0-1,Expected survival period >3 months;\n\n          4. stop medicine > 30 days if any other chemotherapy drugs be used.\n\n          5. HB\u226590g/L,ANC(Absolute Neutrophil Count) \u22651.5\u00d7109/L\uff1bPLT \u2265100\u00d7109/L\n             ,BIL/ALT/AST(aspartate aminotransferase )/Cr in normal range,or CCR\u226560ml/min,TG\u2264\n             3.0mmol/L\uff0ccholesterol\u22647.75mmol/L; LVEF\u2265LLN.\n\n          6. Female should be agreed to use contraceptive during the study and after 6 months\n             (such as intrauterine device(IUD), the pill or a condom); The serum or urine\n             pregnancy test negative before take ALTN, and is out of non-lactation period. Male\n             should be agreed to use contraceptive during the study and after the period of 6\n             months.\n\n          7. Volunteer, informed consent form (ICF) signed, compliance.\n\n        Exclusion Criteria:\n\n          1. Subject was diagnosed with other malignant tumors previously or meanwhile;\n\n          2. Participated in other clinical trials in four weeks;\n\n          3. Has influence of oral drugs(such as unable to swallow, gastrointestinal tract after\n             resection);\n\n          4. Already diagnosed with brain metastases, spinal cord compression, cancerous\n             meningitis, or screening CT or MRI findings of the brain or soft meningeal disease\n             patient;\n\n          5. Hypertension\n\n          6. Urine protein: ++, and urinary in 24 hours > 1.0g;\n\n          7. Coagulant function abnormality: subject with bleeding tendency (such as active peptic\n             ulcer) or are receiving thrombolysis or anticoagulant therapy;\n\n          8. Subject with psychiatric drugs abuse history and can't get rid of, or mental\n             disorder;\n\n          9. With artery/venous thrombotic before oral ALTN;\n\n         10. With history of anticoagulant, vitamin K antagonists(such as warfarin or heparin) or\n             other analogues treatment;\n\n         11. With Abnormal thyroid function;\n\n         12. With history of psychiatric drugs abuse or a mental disorder;\n\n         13. Viral hepatitis B or hepatitis c patients (including hepatitis b, hepatitis c virus\n             carriers);\n\n         14. Have immunodeficiency history;\n\n         15. According to the researcher's judgment,there are concomitant diseases which will\n             seriously endanger the patients or obstruct the patients to complete the clinical\n             trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01833923", 
            "org_study_id": "ALTN-I-01"
        }, 
        "intervention": {
            "arm_group_label": "anlotinib hydrochloric capsule", 
            "description": "oral medicine.", 
            "intervention_name": "anlotinib hydrochloric  capsule", 
            "intervention_type": "Drug", 
            "other_name": "ALTN"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Advanced cancer", 
        "lastchanged_date": "September 16, 2013", 
        "location": {
            "contact": {
                "last_name": "Yihebali Chi, doctor"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100021"
                }, 
                "name": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
            }, 
            "investigator": {
                "last_name": "Yongkun Sun, doctor", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of Anlotinib Hydrochloric Capsule on Tolerance and Pharmacokinetics", 
        "other_outcome": {
            "description": "To evaluate the effectiveness of ALTN by enhanced CT scan every two cycles. Refer to recist 1.1.", 
            "measure": "tumor size", 
            "safety_issue": "No", 
            "time_frame": "Up to 42 days"
        }, 
        "overall_contact": {
            "email": "yihebalichi@yahoo.com.cn", 
            "last_name": "Yihebali Chi, doctor"
        }, 
        "overall_official": {
            "affiliation": "Cancer Institude and hospital,CAMS", 
            "last_name": "Yihebali Chi, doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To collect point with single drug:H0/H0.5/H1/H2/H4/H8/H12/H24/H48/H72/H96/H120/H144/H/H168/H192/H216/H240\nTo collect point with multiple drug:d1/d2/d4/d7/d10/d14/d15/d21/d22/d28/d35/d42", 
            "measure": "Tmax Cmax t1/2 AUC", 
            "safety_issue": "No", 
            "time_frame": "Up to 52 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01833923"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "blood examination, urine examination, stool examination, blood biochemical  (ALT, AST, TB(total bilirubin), DB, BUN, Cr, blood electrolyte), electrocardiogram (ecg), thyroid function, the function of blood coagulation, etc", 
            "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 21 days"
        }, 
        "source": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
        "sponsors": {
            "collaborator": {
                "agency": "Nanjing Medical University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}